Association for Research in Otolaryngology (ARO) Midwinter Meeting, Feb 5-9, 2022

CBSET and our partner, CILcare, will be presenting at the Association for Research in Otolaryngology (ARO) 45th Annual Midwinter Meeting, February 5-9, 2022. (NOTE: This meeting is now entirely virtual.)

The workshop, entitled “Translational Delivery Approaches for Inner Ear Therapies” will be held on February 7, 2022, from 8-11am PST (11am-1pm EST). Rami Tzafriri, Director of Research and Innovation at CBSET and Professor Peter Steyger, Ph. D., Director of the Translational Hearing Center, Creighton University, are co-chairing the workshop.

REGISTER HERE

This workshop will provide an interactive opportunity to discuss the challenges and opportunities of inner ear delivery technology, and emerging approaches toward safe and efficacious dosing of emerging therapeutic compounds. We will cover the different aspects of inner ear delivery, from promising therapeutic strategies to small molecules and cell therapy. It will aim to clarify the translation of delivery approaches used in preclinical animal models to clinical trials in patients. Discussion will focus on practical aspects, including the experience of local delivery in the middle and inner ear in preclinical animal models, with a focus on preclinical delivery case studies and challenges for delivery in humans.


Agenda:

  • Delivery approaches to the inner ear used in animal models, by Gaëlle Naert, PhD, Chief Operations Officer, CILcare, France
  • Factors in Intratympanic Drug Delivery for the Inner Ear, by Bonnie Jacques, PhD, Senior Director, Research & Preclinical Development, Otonomy, USA
  • Local delivery of inner ear gene therapies by Laurent Désiré, PhD, Preclinical Development Director, Sensorion, France
  • Challenges in delivering novel therapeutics to the inner ear in humans by Ronald Pennings, MD, PhD, ENT surgeon, Radboud UMC, Nijmegen, The Netherlands

CILcare will also present 3 posters:

  • Development of noise-induced hearing loss (NIHL) rat models for preclinical efficacy assessment, by Carolanne Coyat, PhD, R&D project Manager
  • Ototoxic effects of drugs used in COVID-19 therapies in comparison to well-known ototoxic agent (Gentamicin) in male Wistar rats, by Sylvie Pucheu, Chief Scientific Officer
  • Reversible impulse noise induced hidden hearing loss, metabolic disturbances and hair cell ciliary changes in mice, by Paul Gratias, PhD student

If you would like to schedule an e-meeting with CBSET before, during or after the event, please contact us. If you would like schedule an e-meeting with CILcare before, during or after the event, please contact them.


Related CBSET Services:

Related CBSET & CILcare Publications:

wpt-cbset-cilcare-cover
World Pharma Today: Auditory Therapy, Ototoxicity, and GLP Compliance: Will the promising market for ear disorder treatments follow ophthalmology’s dramatic growth curve?

by Michael Naimark, Director of Business Development, CBSET, Inc. and Marie-Pierre Pasdelou, PharmD, founder and the Chief Development Officer, CILcare

wpt-stem-cell-auditory-coverWorld Pharma Today: Stem Cell and Regenerative Therapies for Hearing Loss

by Michael Naimark, Director of Business Development, CBSET, Inc. and Marie-Pierre Pasdelou, PharmD, founder and the Chief Development Officer, CILcare